Abbott (NYSE:ABT) stock fell despite a Q1 Revenue beat as Medical Devices growth, FreeStyle Libre Demand and Exact Sciences dilution shaped ABT’s 2026 outlook.

Key Highlights

  • Abbott reported Q1 2026 revenue of $11.16 billion and adjusted EPS of $1.15, both ahead of consensus.
  • Medical Devices revenue grew 13.2%, supported by FreeStyle Libre CGM systems and broader device demand.
  • Abbott cut full-year EPS guidance to $5.38-$5.58, including $0.20 of dilution from the Exact Sciences Acquisition.

Abbott Laboratories (NYSE:ABT) is one of the most-watched US large-cap healthcare stocks. With a market Capitalization of about $147.13 billion, ABT continues to lead in diversified medical devices and diagnostics. Shares fell 0.51%.

Why the Stock Is in Focus Today

Abbott released Q1 2026 results on April 16 with revenue of $11.16 billion and adjusted EPS of $1.15, both ahead of consensus. Revenue rose 7.78% year over year. Medical devices grew 13.2% on a reported basis, supported by FreeStyle Libre CGM systems and expanded CMS reimbursement in the US. The company trimmed full-year EPS guidance to $5.38-$5.58, citing $0.20 of dilution from the $21 billion Exact Sciences acquisition closed in March.

The board declared a $0.63 quarterly Dividend payable May 15, 2026.

Latest Share Price Movement

ABT traded at $84.47, down 0.51% on the day, with Volume of 12.91 million shares and a relative volume reading of 0.94.

Key News Driving Investor Attention

Three news items dominate. First, the Q1 revenue beat. Second, the Exact Sciences acquisition closing and EPS dilution. Third, the dividend declaration.

Earnings and Financial Performance

Diluted EPS on a trailing-twelve-month basis stands at $3.59 with EPS growth of -53.44% year over year. The TTM trajectory reflects acquisition-related accounting impacts; underlying operations remain healthy.

Analyst and Market Sentiment

Analyst sentiment on ABT is moderately positive. Bulls highlight FreeStyle Libre and the diagnostics Franchise; bears watch ongoing litigation risk and the integration of Exact Sciences.

Sector Outlook

Abbott competes in medical devices with Medtronic, Stryker and Boston Scientific, in diagnostics with Roche and Danaher, and in nutrition with Nestle and Reckitt.

Risks Investors Are Watching

Risks include litigation risk, integration of Exact Sciences, competitive dynamics in continuous glucose monitoring and FX exposure on international sales.

What to Watch Next

Catalysts ahead include Q2 2026 results, Exact Sciences integration milestones and updates on FreeStyle Libre adoption.

Conclusion

Abbott’s Q1 2026 results show a mixed setup for ABT. Revenue and adjusted EPS were ahead of expectations, while Medical Devices remained the strongest operating pillar. However, the Exact Sciences acquisition reduced near-term earnings guidance and added integration risk. The next phase for Abbott will depend on FreeStyle Libre adoption, diagnostics execution and whether acquisition-related dilution can be absorbed without weakening the company’s longer-term healthcare growth profile.